AlphaMark Advisors LLC Sells 3,292 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

AlphaMark Advisors LLC lessened its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 92.0% in the 4th quarter, Holdings Channel.com reports. The fund owned 286 shares of the medical equipment provider’s stock after selling 3,292 shares during the period. AlphaMark Advisors LLC’s holdings in Lantheus were worth $26,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Signaturefd LLC increased its stake in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares during the period. UMB Bank n.a. increased its stake in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after buying an additional 126 shares during the period. GAMMA Investing LLC lifted its holdings in Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after buying an additional 146 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Lantheus in the 3rd quarter valued at about $25,000. Finally, CWM LLC grew its stake in Lantheus by 63.0% in the 3rd quarter. CWM LLC now owns 750 shares of the medical equipment provider’s stock worth $82,000 after acquiring an additional 290 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Price Performance

LNTH opened at $97.50 on Monday. The firm has a market capitalization of $6.78 billion, a PE ratio of 16.22 and a beta of 0.46. The business’s 50-day moving average is $91.11 and its two-hundred day moving average is $100.53. Lantheus Holdings, Inc. has a 1 year low of $50.42 and a 1 year high of $126.89.

Analysts Set New Price Targets

A number of brokerages recently issued reports on LNTH. JMP Securities reiterated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Truist Financial restated a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, The Goldman Sachs Group started coverage on Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $131.86.

Insider Transactions at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.